The second of two potential drugs for immune system disorders that are together expected to bring in peak annual revenues of between $3 billion and $7 billion to Sanofi Genzyme and a New York based partner in the next few years is expected to have a decision on U.S. approval by next spring.
Both drugs are partnered between the Cambridge-based division of Sanofi (NYSE: SNY) that’s focused on specialty pharmaceuticals (formerly called simply Genzyme), and Tarrytown, N.Y.-based Regeneron Pharmaceuticals (Nasdaq: REGN).
